The director of this ASX company just made another sizeable share purchase

More insider buying action has failed to prop up the Polynovo share price.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares backtrack 4.6% to $1.14 
  • Polynovo chair, David Williams topped up his holdings through an on-market trade of close to 80,000 shares 
  • Since the beginning of May, Mr Williams has spent around $4.65 million on Polynovo shares 

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is faring no better.

During early afternoon trade, the medical device company's shares are swapping hands at $1.14, down 4.6%.

This comes despite Polynovo announcing another sizeable share purchase from one of its directors.

For context, the All Ordinaries Index (ASX: XAO) is 0.95% in the red to 7,391.9 points.

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone

Image source: Getty Images

Polynovo insider buying action continues

Following the recent market slump, the company's chair, David Williams has decided to take advantage of the Polynovo share price weakness.

According to its release, Polynovo advised that Mr Williams has bought 79,557 shares at a price of $1.1849 apiece. This was conducted via an on-market trade by Mr Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equates to a value of more than $94,000.

Following the latest purchase, this means that Mr Williams now has over 23.24 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in reflects that a number of insiders, particularly Mr Williams believe Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents.

It's also worth noting that Mr Williams has made a number of purchases since the beginning of May 2022. In fact, he has spent around $4.65 million over that time.

Polynovo share price summary

Despite this month's 19% gain, Polynovo shares have fallen by 55% in the past 12 months.

Year to date, its shares are down roughly 25%.

Based on today's price, Polynovo presides a market capitalisation of approximately $817.18 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor looks unsure.
Healthcare Shares

CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September?

Find out why investors are now rushing to buy CSL shares.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Could this 7%-yielding ASX healthcare share be a growth winner?

The current weakness could be catching the eye of passive income investors.

Read more »

Two scientists looking at a tablet.
Healthcare Shares

CSL shares are up more than 40% in a month. What just happened in the US?

The stock’s huge rebound is getting another boost.

Read more »

Woman flexes muscles after donating blood.
ASX Share Market News

Where will CSL shares be in 12 months? Brokers weigh in

Analysts remain divided over CSL’s recovery prospects.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why this ASX healthcare share is a retiree's dream for FY27

This defensive business is giving investors rising dividends.

Read more »

Two scientists analysing results on a computer screen.
Broker Notes

Up 88%! Why CSL shares remain an 'appealing' buy today

A top analyst forecasts more outperformance from CSL’s surging shares.

Read more »

Two scientists analysing results on a computer screen.
Earnings Results

Monash IVF Group earnings: FY26 profit slips, outlook improves

The company posted weaker FY26 profit but ends year with improving momentum, dividend, and outlook for growth.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Healthcare Shares

Bell Potter says this ASX healthcare share could rise 200%+

The broker has good things to say about this growing stock.

Read more »